自从1959年 Avery 阐明 RDS 是由于肺表面活性剂缺乏以来,一直沿用机械人工换气和高浓度氧气疗法。1979年日本首先研制出表面活性剂 TA 经各种临床试验后,1987年12月开始投放市场出售补充肺表面活性剂前,首先要作出正确的 RDS诊断,否则有导致窒息的危险,其次要使新生儿稳定。RDS 是起因于表面活性物质缺乏而发展为无气肺、血氧过少,再加上各种病的因素而形成的一个综合征。其主要因素之一是休克和心衰,此种病状情况下,即使补充表面活性剂也几乎毫无效果。补充表面活性剂后15分钟无效的17例中有12例伴重症窒息或休克。如血压低应先用多巴胺或输血浆治 Since 1959, Avery has clarified RDS is due to lack of pulmonary surfactant, has been using mechanical ventilation and high concentrations of oxygen therapy. In 1979, Japan first developed a surfactant TA after various clinical trials, started in December 1987 to put on the market to sell supplemental pulmonary surfactant, we must first make the correct diagnosis of RDS, otherwise there is the risk of causing suffocation, and secondly to make Neonatal stable. RDS is a syndrome that develops as a result of lack of surfactant and development of airless lungs, hypoxemia, and various disease conditions. One of the main factors is shock and heart failure, even in the case of such conditions, even if the surfactant is added with almost no effect. Twelve of the 17 patients who were inactive 15 minutes after surfactant replenishment had severe asphyxia or shock. Such as low blood pressure should be treated with dopamine or plasma